biologic

Change of Ownership for US CDMO Alcami

UK specialist healthcare investor GHO Capital Partners and US investment firm The Vistria Group have entered into an agreement to buy a controlling interest in US CDMO Alcami from current private equity owners Madison Dearborn Partners (MDP) and Ampersand Capital Partners. Financial terms of the deal were not disclosed.

Topics • Strategy

The Need for Innovation in Pharmaceutical Manufacturing

News

Sanofi Sues US Merck over Insulin Drug

News

Janssen Boosts Metabolism Portfolio with Hanmi Biologic

Top-Feature

SCIEX

Capillary Electrophoresis in Biotherapeutic Development: Platform Methods, Fragment Workflows, and ADC Characterization

Agilent Technologies Inc.

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

Evonik Industries AG

Safer, Scalable Pharmaceutical Manufacturing with Flow Chemistry

Citrine

Operationalizing AI in Polymer Development: How Syensqo Is Scaling Impact with the Citrine Platform

Global Impact Coalition (GIC)

Siemens Joins the Global Impact Coalition

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

Article

Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Frost & Sullivan